Clinical evaluation of estramustine phosphate and vinblastine in patients with hormone-refractory prostate cancer
Awakura, Y.; Yamamoto, M.; Fukuzawa, S.; Itoh, N.; Nonomura, M.; Fukuyama, T.
Hinyokika Kiyo. Acta Urologica Japonica 46(7): 449-452
2000
ISSN/ISBN: 0018-1994 PMID: 10965448 Document Number: 522809
We evaluated the efficacy of the combination of estramustine phosphate and vinblastine in 13 patients with hormone-refractory prostate cancer. Of 12 patients with an elevated prostate specific antigen (PSA) level at the start of treatment, 5 (42%) had a greater than 50% decrease in PSA level. In a patient with cervical and mediastinal lymph node metastases, about a 57% decrease was observed in bidimensional measurement. Side effects were mild and manageable. The survival rate was not significantly different between patients who showed a greater than 50% decrease in PSA levels or regression of lymph node metastases versus the other patients.